Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme acquires Verigen AG for up to $50mm

Executive Summary

Genzyme has acquired privately held Verigen AG (cell therapy for cartilage repair) for $10mm in cash. It may also pay earn-outs of up to $40mm over the next six years based on the achievement of development (BLA and US marketing approval) and sales milestones.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Biomaterials
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register